Article in Journal of neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Chase E TaylorDepartment of Neuroscience, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0002-9466-606X
Laura E MendenhallSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0003-2027-9670
Michael D SunshineSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0002-7133-4185
Jessica N WilsonDepartment of Neuroscience, University of Kentucky, Lexington, Kentucky, United States.ORCID 0009-0003-8453-1270
Chris M CalulotSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky, United States.
Ramon C SunDepartment of Biochemistry & Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, United States.
Lance A JohnsonDepartment of Physiology, University of Kentucky, Lexington, Kentucky, United States.
Warren J AlilainDepartment of Neuroscience, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0003-4502-8878
Funding
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathiesP20GM148326 · NIGMS · UNIVERSITY OF KENTUCKY · PI Patrick G Sullivan · 2023 to 2026
$10.6M
Brain Glucose Deficiency: Mechanisms and ModulationRM1NS133593 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Joseph J. Pancrazio, Juan M. Pascual · 2023 to 2026
$5.3M
Deciphering the Glycan Code in Human Alzheimer’s Disease BrainR01AG078702 · NIA · UNIVERSITY OF KENTUCKY · PI Peggi M Angel, Sean Curtis Bendall · 2022 to 2026
$3.8M
A targeted analytical framework to optimize posthospitalization delirium pharmacotherapy in patients with Alzheimers disease and related dementiasR01AG081412 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOSHUA K LIN · 2023 to 2026
$3.4M
Aberrant Glycogen in Lung Adenocarcinoma TumorigenesisR01CA266004 · NCI · UNIVERSITY OF KENTUCKY · PI Matthew S. Gentry, Ramon C. Sun · 2022 to 2026
$2.6M
APOE Allele Switching as a Therapeutic Approach for Alzheimer's DiseaseR01AG080589 · NIA · UNIVERSITY OF KENTUCKY · PI Lance Allen Johnson · 2023 to 2026
$2.6M
APOE and the PPP: Glucose Metabolism and Oxidative Stress in Alzheimer's DiseaseR01AG060056 · NIA · UNIVERSITY OF KENTUCKY · PI JOHNSON, LANCE ALLEN · 2018 to 2022
$2.5M
Assessing the role of APOE in glial lipid droplet metabolism and functionR01AG081421 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sarah Cohen, Lance Allen Johnson · 2023 to 2026
$2.4M
Examining the Effects of the Neuroprotective APOE2 Allele on Peripheral ImmunometabolismR01AG062550 · NIA · UNIVERSITY OF KENTUCKY · PI JOHNSON, LANCE ALLEN · 2019 to 2023
$2.2M
Aberrant Glycogen Modulates Cerebral Glucose Metabolism in Aging and Alzheimer's DiseaseR01AG066653 · NIA · UNIVERSITY OF KENTUCKY · PI SUN, RAMON C. · 2020 to 2024
$1.9M
Targeting Glycogen Metabolism in Ewing's Sarcoma: Diagnostic, Prognostic, and Therapeutic ApplicationsR01CA288696 · NCI · UNIVERSITY OF FLORIDA · PI Matthew S. Gentry, Ramon C. Sun · 2024 to 2026
$1.8M
Alzheimer's Association (AA)Craig H. Neilsen FoundationHHS | NIH | National Cancer Institute (NCI) CA266004HHS | NIH | National Institute on Aging (NIA) AG060056HHS | NIH | National Institute on Aging (NIA) AG065220HHS | NIH | National Institute on Aging (NIA) AG066653HHS | NIH | National Institute on Aging (NIA) AG078702HHS | NIH | National Institute on Aging (NIA) AG081412HHS | NIH | National Institute on Aging (NIA) AG80589Kentucky Spinal Cord and Head Injury Research TrustNCI NIH HHS R01 CA266004NCI NIH HHS R01 CA288696NIA NIH HHS R01 AG060056NIA NIH HHS R01 AG062550NIA NIH HHS R01 AG066653NIA NIH HHS R01 AG078702NIA NIH HHS R01 AG080589NIA NIH HHS R01 AG081412NIA NIH HHS R01 AG081421NIGMS NIH HHS P20 GM148326NINDS NIH HHS RM1 NS133593V Foundation for Cancer Research (VFCR)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.